CROI 2026 Resources (For Registered Attendees Only)
You must be logged in to view this content. Email Address Password Remember Me Log In…
Interplay of Cholesterol and Env Protein in the Lytic Deformation of HIV-1 by Peptide Triazoles
…p24, from the viral lumen. Examining the effects of cholesterol on p24 release allows us to investigate lipid-protein interplay at the Env spike. Methodology: Cholesterol was extracted from BaL.01 (HIV-1)…
High Rate of HIV Superinfection After Delivery: Secondary Analysis of the PEPI Trial
…of post-partum SI in HIV-infected women from the Post-Exposure Prophylaxis of Infants (PEPI) trial in Malawi, and evaluated if SI is associated with an increased risk of postnatal mother-to-child transmission…
50 – Empowering Communities: Peer-Based Model for Expanding Equitable Access to PrEP & PEP in Mexico
…Participants connect via social media, enroll through a digital platform, and access testing and medication either in person or via courier services. Personalized counseling ensures informed use of PrEP (daily…
IMPACT OF AGING ON ART CONTINUATION FOR PERFORMANCE MANAGEMENT AND TARGET SETTING
…into and out of age bands. This analysis quantifies the impact of aging on PEPFAR retention estimates for eight PEPFAR priority countries: Kenya, Mozambique, Nigeria, South Africa, Tanzania, Uganda, Zambia,…
856 – Human Antibody Repertoire and Allograft Rejection Among Kidney Transplant Recipients With HIV
…with 5%-95% reactivity were included: 4667 viral peptides and 130 viral species, 667 toxin peptides, and 1427 human peptides. We used continuous Viral Aggregate Reactivity score (VARscore) to integrate the…
50 – Empowering Communities: A Peer-Based Model for Expanding Equitable Access to PrEP and PEP in Mexico
…Participants connect via social media, enroll through a digital platform, and access testing and medication either in person or via courier services. Personalized counseling ensures informed use of PrEP (daily…
747 – Predictors of HIV Drug Resistance to Dolutegravir in 4 PEPFAR-Supported Countries
…83 had DTG DR. About 9 in 10 individuals were transitioned to DBR from another regimen. Median age was 36.2 years (95%CI 28-43), median time on a DBR was 1.5…
PEPFAR/Global Fund at 10 years: Past, Present, and Future
Background: The presentation will review the achievements and major lessons learned from the implementation of President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis…
280 – B-Cell Immunogenicity of a Fusion Peptide HIV Vaccine in Adults: Results From HVTN 303 Part B
Background HVTN 303, a trial of HIV-1 fusion peptide (FP)-directed vaccine, was designed to prime FP-binding antibodies with neutralizing potential. An 8-amino acid peptide (FP8) was conjugated to the heavy…